Results 231 to 240 of about 308,418 (340)

Paclitaxel: Infusion Duration Effect on Toxicity and Efficacy

, 1995
Cheryl Tate
openalex   +1 more source

Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis [PDF]

, 2000
Chun‐Ming Huang, Ying‐Ta Wu, Shui-Tein Chen   +2 more
openalex   +1 more source

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

BMEMat, EarlyView.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen, Ying Yao, Yan Zhang, Xinyu Shi, Ling Bai, Yang Zhong, Yan Zhang, Kun Zhang   +7 more
wiley   +1 more source

Comments on the SERAPHINA study assessing the utilization, efficacy, safety, and quality of life of nab-paclitaxel in patients with advanced HER2-negative breast cancer. [PDF]

J Cancer Res Clin Oncol
Altundag K.
europepmc   +1 more source

The History of Paclitaxel

, 2008
openaire   +3 more sources

Correction to “Improved Antiglioblastoma Activity and BBB Permeability by Conjugation of Paclitaxel to a Cell‐Penetrative MMP‐2‐Cleavable Peptide”

Advanced Science, EarlyView.
wiley   +1 more source

Harnessing nanomaterials to precisely regulate the immunosuppressive tumor microenvironment for enhanced immunotherapy

BMEMat, EarlyView.
The immunosuppressive tumor microenvironment, characterized by hypoxia, redox imbalance, elevated interstitial fluid pressure, and acidity, was comprehensively elucidated. This review discussed the etiology and consequences of the characteristics of the immunosuppressive tumor microenvironment, and analyzed the recent advancements in nanomaterials for ...
Wen Zhang, Xueyin Hu, Wei Cheng, Lumeng Zhang, Yuanfang Chen, Qinrui Fu, Luntao Liu, Saijun Fan   +7 more
wiley   +1 more source

Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors

, 1998
Mace L. Rothenberg, A. Sharma, Geoffrey R. Weiss, Miguel A. Villalona‐Calero, John R. Eckardt, C. Aylesworth, Maura A. Kraynak, David Rinaldi, Gladys Rodriguez, H. A. Burris, S. Gail Eckhardt, Connie Stephens, Kelly Forral, Steven J. Nicol, Daniel D. Von Hoff   +14 more
openalex   +1 more source

Advancing design strategies in smart stimulus‐responsive liposomes for drug release and nanomedicine

BMEMat, EarlyView.
Schematic illustration of stimulus‐responsive liposomes designed for controlled drug release and nanomedicine. The innermost circle represents different liposomal structures, including unilamellar, multilamellar, and multivesicular liposomes. The middle layer illustrates the responsive phospholipid components.
Yuchen Guo, Nan Li, Daiwei Zhang, Jingya Gu, Zhihuan Liao, Zihao Teng, Xiangfu Du, Peter S. Timashev, Shipeng Chen, Shuaidong Huo   +9 more
wiley   +1 more source

Comparative Efficacy and Cycle-Wise Toxicity of Paclitaxel-Carboplatin Versus Gemcitabine-Cisplatin in Stage IV Non-small Cell Lung Cancer (NSCLC): A Quasi-experimental Study in Bangladesh. [PDF]

Cureus
Bin Sharif MR, Alam AMMS, Iqbal HMN, Ayub SBA, Habibur Rahaman M.   +4 more
europepmc   +1 more source